The SIBERIA Trial (Acculink™ Versus CGuard™)

Independent Randomized Trial in Carotid Artery Revascularization Comparing the Stent (Acculink™) Versus the Mesh Covered Stent (CGuard™) was performed.

Ischemic lesions of brain after CAS were determined by MRI before and after treatment (2-3 days, 1 month).

Inclusion criteria

• Consecutive patients 45-80 years old accepted for CAS following neurological consultation and qualification for the procedure according to center's routine practice.
• More than 6-month life expectancy
• Suitable clinical conditions for performing DW-MRI
• Written Informed consent approved by the Ethics Committee
• Subject agrees to all required follow-up procedures and visits

Exclusion criteria

• Currently enrolled in another investigational device or drug study that has not completed the study or that clinically interferes with the current study endpoints
• Recent surgical procedure within 30-days before or planned surgery within 30-days after the stenting procedure
• Hepatic active disease (bilirubin> 35 mmol / l) or renal insufficiency (serum creatinine > 2.5 mg/dL or glomerular filtration rate <60 ml / min)
• Recent evolving acute stroke within 30-days of study evaluation
• Myocardial infarction within 72 hours prior to carotid stenting procedure (CPK-MB > 3 times normal)
• Female patients of childbearing potential or known to be pregnant
• Any known factor for potential stroke other than carotid stenosis, such as atrial fibrillation or atrial flutter (paroxysmal, permanent or persistent) or thrombophilia
• Patient on VKA or new oral anticoagulants